Lexaria Bioscience Corp.https://investorshangout.com/Lexaria-Bioscience-Corp-LEXX-94337/en-usSun, 18 Oct 2026 02:17:04 GMTCopyright InvestorsHangout.comNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities inhttps://investorshangout.com/post/view?id=6733206https://investorshangout.com/post/view?id=6733206Tue, 03 Dec 2024 20:00:21 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3https://investorshangout.com/post/view?id=6720821https://investorshangout.com/post/view?id=6720821Fri, 27 Sep 2024 21:16:02 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Indushttps://investorshangout.com/post/view?id=6719512https://investorshangout.com/post/view?id=6719512Fri, 20 Sep 2024 21:24:30 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerablehttps://investorshangout.com/post/view?id=6719506https://investorshangout.com/post/view?id=6719506Fri, 20 Sep 2024 21:07:14 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Perforhttps://investorshangout.com/post/view?id=6718928https://investorshangout.com/post/view?id=6718928Tue, 17 Sep 2024 22:55:08 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Dhttps://investorshangout.com/post/view?id=6718324https://investorshangout.com/post/view?id=6718324Fri, 13 Sep 2024 20:16:58 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO https://investorshangout.com/post/view?id=6717043https://investorshangout.com/post/view?id=6717043Fri, 06 Sep 2024 21:06:44 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TMhttps://investorshangout.com/post/view?id=6716861https://investorshangout.com/post/view?id=6716861Thu, 05 Sep 2024 21:04:55 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceuhttps://investorshangout.com/post/view?id=6716858https://investorshangout.com/post/view?id=6716858Thu, 05 Sep 2024 20:57:34 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreementhttps://investorshangout.com/post/view?id=6716456https://investorshangout.com/post/view?id=6716456Tue, 03 Sep 2024 21:34:58 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PKhttps://investorshangout.com/post/view?id=6716080https://investorshangout.com/post/view?id=6716080Thu, 29 Aug 2024 20:31:46 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second Ghttps://investorshangout.com/post/view?id=6715703https://investorshangout.com/post/view?id=6715703Tue, 27 Aug 2024 20:13:38 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Validates Technology’s Superiority, Moving Closer to a Shhttps://investorshangout.com/post/view?id=6715535https://investorshangout.com/post/view?id=6715535Mon, 26 Aug 2024 20:57:42 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Rhttps://investorshangout.com/post/view?id=6714864https://investorshangout.com/post/view?id=6714864Thu, 22 Aug 2024 20:01:34 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Animal Stuhttps://investorshangout.com/post/view?id=6714636https://investorshangout.com/post/view?id=6714636Wed, 21 Aug 2024 19:59:30 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molehttps://investorshangout.com/post/view?id=6714186https://investorshangout.com/post/view?id=6714186Mon, 19 Aug 2024 20:28:21 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Oral GLP-1 Alternatives for Diabetes and Obesithttps://investorshangout.com/post/view?id=6713757https://investorshangout.com/post/view?id=6713757Fri, 16 Aug 2024 20:03:51 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Opportunity from First-Ever Wohttps://investorshangout.com/post/view?id=6713753https://investorshangout.com/post/view?id=6713753Fri, 16 Aug 2024 19:52:55 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Q3 2024 Financial Results; Offers a Roadmap for https://investorshangout.com/post/view?id=6711895https://investorshangout.com/post/view?id=6711895Mon, 12 Aug 2024 22:21:52 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity Treatmentshttps://investorshangout.com/post/view?id=6711168https://investorshangout.com/post/view?id=6711168Thu, 08 Aug 2024 21:11:23 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases “Noteworthy” Weight-Loss Reshttps://investorshangout.com/post/view?id=6710663https://investorshangout.com/post/view?id=6710663Tue, 06 Aug 2024 20:05:20 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Produces Notable Findings in Latest Weight Loss Studyhttps://investorshangout.com/post/view?id=6709794https://investorshangout.com/post/view?id=6709794Wed, 31 Jul 2024 21:55:17 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful Ghttps://investorshangout.com/post/view?id=6708080https://investorshangout.com/post/view?id=6708080Mon, 22 Jul 2024 21:03:42 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Issuance of Three New Patents, Growing Portfolio https://investorshangout.com/post/view?id=6707235https://investorshangout.com/post/view?id=6707235Wed, 17 Jul 2024 19:45:46 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Inhttps://investorshangout.com/post/view?id=6707224https://investorshangout.com/post/view?id=6707224Wed, 17 Jul 2024 19:29:46 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans https://investorshangout.com/post/view?id=6707040https://investorshangout.com/post/view?id=6707040Tue, 16 Jul 2024 20:22:32 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Follohttps://investorshangout.com/post/view?id=6706788https://investorshangout.com/post/view?id=6706788Mon, 15 Jul 2024 20:32:17 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Humahttps://investorshangout.com/post/view?id=6705680https://investorshangout.com/post/view?id=6705680Tue, 09 Jul 2024 21:35:41 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures New Patents for Antiviral Druhttps://investorshangout.com/post/view?id=6705378https://investorshangout.com/post/view?id=6705378Mon, 08 Jul 2024 20:26:47 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Favorable Strategic Partneringhttps://investorshangout.com/post/view?id=6703542https://investorshangout.com/post/view?id=6703542Thu, 27 Jun 2024 20:53:17 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2https://investorshangout.com/post/view?id=6702756https://investorshangout.com/post/view?id=6702756Mon, 24 Jun 2024 20:14:04 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Engages CRO for DehydraTECH GLP-1 Humhttps://investorshangout.com/post/view?id=6701715https://investorshangout.com/post/view?id=6701715Tue, 18 Jun 2024 20:53:26 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO; Set for First Tirzepatide Molecule Study https://investorshangout.com/post/view?id=6701501https://investorshangout.com/post/view?id=6701501Mon, 17 Jun 2024 20:58:29 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwidehttps://investorshangout.com/post/view?id=6699236https://investorshangout.com/post/view?id=6699236Thu, 06 Jun 2024 21:35:57 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Seconhttps://investorshangout.com/post/view?id=6699019https://investorshangout.com/post/view?id=6699019Wed, 05 Jun 2024 20:59:33 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Shttps://investorshangout.com/post/view?id=6696889https://investorshangout.com/post/view?id=6696889Tue, 28 May 2024 21:19:19 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilohttps://investorshangout.com/post/view?id=6696063https://investorshangout.com/post/view?id=6696063Thu, 23 May 2024 21:02:24 GMTNetworkNewsWire: NetworkNewsBreaks – SUIC Worldwide Holdings Ltd (SUIC) Targeting Sustained Growth Driven by Cuttihttps://investorshangout.com/post/view?id=6695745https://investorshangout.com/post/view?id=6695745Wed, 22 May 2024 20:55:42 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Granted Two New US Patents in Hypertehttps://investorshangout.com/post/view?id=6695742https://investorshangout.com/post/view?id=6695742Wed, 22 May 2024 20:52:59 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Commencement of Dosing in Chttps://investorshangout.com/post/view?id=6694575https://investorshangout.com/post/view?id=6694575Fri, 17 May 2024 21:16:44 GMTNetworkNewsWire: NetworkNewsBreaks – – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Tap into Various Growinghttps://investorshangout.com/post/view?id=6694244https://investorshangout.com/post/view?id=6694244Thu, 16 May 2024 20:29:52 GMTNetworkNewsWire: NetworkNewsBreaks – – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Tap into Various Growinghttps://investorshangout.com/post/view?id=6694243https://investorshangout.com/post/view?id=6694243Thu, 16 May 2024 20:29:31 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners with the National Research Council of Canada forhttps://investorshangout.com/post/view?id=6693641https://investorshangout.com/post/view?id=6693641Tue, 14 May 2024 21:02:05 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Extend Operational Runway to 2025 Following Warranhttps://investorshangout.com/post/view?id=6692455https://investorshangout.com/post/view?id=6692455Thu, 09 May 2024 20:41:53 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing of Human Pilot Study Nohttps://investorshangout.com/post/view?id=6692064https://investorshangout.com/post/view?id=6692064Wed, 08 May 2024 20:43:48 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Marketshttps://investorshangout.com/post/view?id=6691695https://investorshangout.com/post/view?id=6691695Tue, 07 May 2024 21:05:24 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Marketshttps://investorshangout.com/post/view?id=6691694https://investorshangout.com/post/view?id=6691694Tue, 07 May 2024 21:05:08 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evalhttps://investorshangout.com/post/view?id=6691344https://investorshangout.com/post/view?id=6691344Mon, 06 May 2024 21:04:06 GMTNetworkNewsWire: NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces $4.7M Warrant Exercise Agrehttps://investorshangout.com/post/view?id=6690003https://investorshangout.com/post/view?id=6690003Wed, 01 May 2024 20:53:12 GMTNetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks GLP-1 Study Milestone with Ethics Review Board Apprhttps://investorshangout.com/post/view?id=6687089https://investorshangout.com/post/view?id=6687089Mon, 22 Apr 2024 21:00:20 GMT